Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 132

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Circulating and Fecal microRNAs as Biomarkers for Inflammatory Bowel Diseases

Schönauen, Katharina, Le, Nha, von Arnim, Ulrike, Schulz, Christian, Malfertheiner, Peter, Link, Alexander · 2018 · Inflammatory Bowel Diseases

Abstract

Background: Assessment of the disease activity in inflammatory bowel disease (IBD) is essential for adequate treatment management and reliable noninvasive biomarkers for verification of mucosal healing are still needed. MicroRNAs (miRNAs) are differentially expressed in IBD and cancer. We aimed to evaluate the potential of circulating and fecal miRNAs as diagnostic biomarkers for IBD. Methods: In this proof-of-principle study we used 2 independent patient cohorts. Testing cohort (n = 96) included serum and fecal samples from controls (n = 35) and IBD patients (n = 61) including 43 patients with Crohn's disease (CD), 18 with ulcerative colitis (UC) with an active disease (n = 38), or in remission (n = 23). Validation cohort included fecal samples from patients with calprotectin/endoscopy-confirmed active disease (n = 30) or in remission (n = 15). Target-based approach (miR-16, miR-21, miR-155, and miR-223) has been used to evaluate miRNA expression. Results: Sera samples from IBD patients showed higher level of miR-16, miR-21, and miR-223, but not miR-155, compared to controls and was higher in CD than in UC patients. Much stronger miRNA expression changes were observed in feces from IBD patients for all studied miRNAs with highest expression of miR-155 and miR-223 in testing and validation cohorts. MiRNA expression correlated with clinical remission, however, only fecal but not circulating miRNAs, correlated with surrogate parameters such as fecal calprotectin or C-reactive protein. Conclusions: Our data provide a novel evidence for differential expression level of fecal miRNAs in IBD. We demonstrate that miRNAs in feces correlate with disease activity and may be considered as potential tool for the further biomarker research in IBD. 10.1093/ibd/izy046_video1izy046.video15794822319001.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ibd/izy046

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 38

  1. Molodecky, 2012, Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review, Gastroenterology, 142, 46, 10.1053/j.gastro.2011.10.001 · DOI · Paper page
  2. Hugot, 2001, Association of NOD2 leucine-rich repeat variants with susceptibility to crohn’s disease, Nature, 411, 599, 10.1038/35079107 · DOI · Paper page
  3. Ogura, 2001, A frameshift mutation in NOD2 associated with susceptibility to crohn’s disease, Nature, 411, 603, 10.1038/35079114 · DOI · Paper page
  4. Neumann, 2011, New endoscopic approaches in IBD, World J Gastroenterol, 17, 63, 10.3748/wjg.v17.i1.63 · doi:10.3748/wjg.v17.i1.63
  5. Shergill, 2015, The role of endoscopy in inflammatory bowel disease, Gastrointest Endosc, 81, 1101, 10.1016/j.gie.2014.10.030 · DOI · Paper page
  6. Soubières, 2016, Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease, World J Gastrointest Pharmacol Ther, 7, 41, 10.4292/wjgpt.v7.i1.41 · DOI
  7. Konikoff, 2006, Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease, Inflamm Bowel Dis, 12, 524, 10.1097/00054725-200606000-00013 · DOI · Paper page
  8. Sands, 2015, Biomarkers of inflammation in inflammatory bowel disease, Gastroenterology, 149, 1275, 10.1053/j.gastro.2015.07.003 · DOI · Paper page
  9. Cappello, 2016, The role of laboratory tests in crohn’s disease, Clin Med Insights Gastroenterol, 9, 51, 10.4137/CGast.S38203 · DOI
  10. Link, 2010, Fecal microRNAs as novel biomarkers for colon cancer screening, Cancer Epidemiol Biomarkers Prev, 19, 1766, 10.1158/1055-9965.EPI-10-0027 · DOI · Paper page
  11. Shi, 2013, MicroRNA-21 knockout improve the survival rate in DSS induced fatal colitis through protecting against inflammation and tissue injury, PLoS One, 8, e66814, 10.1371/journal.pone.0066814 · DOI · Paper page
  12. Gracias, 2013, The microRNA miR-155 controls CD8(+) T cell responses by regulating interferon signaling, Nat Immunol, 14, 593, 10.1038/ni.2576 · DOI · Paper page
  13. Singh, 2014, Mir-155 deficiency protects mice from experimental colitis by reducing T helper type 1/type 17 responses, Immunology, 143, 478, 10.1111/imm.12328 · DOI
  14. Link, 2013, MicroRNA in gastrointestinal cancer: a step closer to reality, Adv Clin Chem, 62, 221, 10.1016/B978-0-12-800096-0.00006-8 · DOI
  15. Wu, 2008, MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha, Gastroenterology, 135, 1624, 10.1053/j.gastro.2008.07.068 · DOI · Paper page
  16. Takagi, 2010, Increased expression of microRNA in the inflamed colonic mucosa of patients with active ulcerative colitis, J Gastroenterol Hepatol, 25, S129, 10.1111/j.1440-1746.2009.06216.x · DOI · Paper page
  17. Fasseu, 2010, Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease, PLoS One, 5, e13160, 10.1371/journal.pone.0013160 · DOI · Paper page
  18. Wu, 2011, Peripheral blood microRNAs distinguish active ulcerative colitis and crohn’s disease, Inflamm Bowel Dis, 17, 241, 10.1002/ibd.21450 · DOI · Paper page
  19. Archanioti, 2011, Micro-RNAs as regulators and possible diagnostic bio-markers in inflammatory bowel disease, J Crohns Colitis, 5, 520, 10.1016/j.crohns.2011.05.007 · DOI
  20. Kalla, 2015, MicroRNAs: new players in IBD, Gut, 64, 504, 10.1136/gutjnl-2014-307891 · DOI · Paper page
  21. Paraskevi, 2012, Circulating microRNA in inflammatory bowel disease, J Crohns Colitis, 6, 900, 10.1016/j.crohns.2012.02.006 · DOI · Paper page
  22. Shi, 2016, Novel evidence for an oncogenic role of microRNA-21 in colitis-associated colorectal cancer, Gut, 65, 1470, 10.1136/gutjnl-2014-308455 · DOI
  23. Link, 2012, Feasibility of fecal microRNAs as novel biomarkers for pancreatic cancer, Plos One, 7, e42933, 10.1371/journal.pone.0042933 · DOI
  24. Link, 2014, MicroRNA miR-J1-5p as a potential biomarker for JC virus infection in the gastrointestinal tract, Plos One, 9, e100036, 10.1371/journal.pone.0100036 · DOI
  25. Schulz, 2016, Validation of two calprotectin rapid tests in daily routine, Clin Lab, 62, 1249, 10.7754/Clin.Lab.2015.151101 · doi:10.7754/clin.lab.2015.151101
  26. Link, 2015, Differential expression of microRNAs in preneoplastic gastric mucosa, Sci Rep, 5, 8270, 10.1038/srep08270 · DOI
  27. Juzėnas, 2015, Analysis of deregulated microRNAs and their target genes in gastric cancer, PLoS One, 10, 1
  28. Fisher, 2015, MicroRNA in inflammatory bowel disease: translational research and clinical implication, World J Gastroenterol, 21, 12274, 10.3748/wjg.v21.i43.12274 · DOI
  29. Iborra, 2013, Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease, Clin Exp Immunol, 173, 250, 10.1111/cei.12104 · DOI
  30. Zahm, 2014, Rectal microRNAs are perturbed in pediatric inflammatory bowel disease of the colon, J Crohns Colitis, 8, 1108, 10.1016/j.crohns.2014.02.012 · DOI
  31. Polytarchou, 2015, Assessment of circulating microRNAs for the diagnosis and disease activity evaluation in patients with ulcerative colitis by using the nanostring technology, Inflamm Bowel Dis, 21, 2533, 10.1097/MIB.0000000000000547 · DOI
  32. Wang, 2016, Circulating microRNA223 is a new biomarker for inflammatory bowel disease, Medicine, 95, e2703, 10.1097/MD.0000000000002703 · DOI · Paper page
  33. Dalal, 2010, The role of microRNA in inflammatory bowel disease, Gastroenterol Hepatol, 6, 714
  34. Liu, 2016, The host shapes the gut microbiota via fecal microRNA, Cell Host Microbe, 19, 32, 10.1016/j.chom.2015.12.005 · DOI · Paper page
  35. Oertli, 2011, MicroRNA-155 is essential for the T cell-mediated control of helicobacter pylori infection and for the induction of chronic gastritis and colitis, J Immunol, 187, 3578, 10.4049/jimmunol.1101772 · DOI
  36. Johnnidis, 2008, Regulation of progenitor cell proliferation and granulocyte function by microRNA-223, Nature, 451, 1125, 10.1038/nature06607 · DOI · Paper page
  37. Ben-Shachar, 2016, MicroRNAs expression in the ileal pouch of patients with ulcerative colitis is robustly up-regulated and correlates with disease phenotypes, PLoS One, 11, e0159956, 10.1371/journal.pone.0159956 · doi:10.1371/journal.pone.0159956
  38. Lin, 2016, Novel microRNA signature to differentiate ulcerative colitis from crohn disease: A genome-wide study using next generation sequencing, MicroRNA, 5, 222, 10.2174/2211536605666161117113031 · DOI

Cited by

See all 132

Metadata

Authors
Schönauen, K., Le, N., von Arnim, U., Schulz, C., Malfertheiner, P., & Link, A.
Affiliations
Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University, Magdeburg, Germany
Venue
Inflammatory Bowel Diseases
Published
2018-04-12
Volume
24
Issue
7
Pages
1547-1557
ISSN
  • 1078-0998
  • 1536-4844
Cited by
132
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating and Fecal microRNAs as Biomarkers for Inflammatory Bowel Diseases. https://app.cochat.ai/papers/10.1093/ibd/izy046
The paper
Schönauen, K., Le, N., von Arnim, U., Schulz, C., Malfertheiner, P., & Link, A. (2018). Circulating and Fecal microRNAs as Biomarkers for Inflammatory Bowel Diseases. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izy046

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.